Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment

被引:23
|
作者
Karst, Sonja G. [1 ]
Lammer, Jan [1 ]
Mitsch, Christoph [1 ]
Schober, Manuela [1 ]
Mehta, Janhvi [1 ,2 ]
Scholda, Christoph [1 ]
Kundi, Michael [3 ]
Kriechbaum, Katharina [1 ]
Schmidt-Erfurth, Ursula [1 ]
机构
[1] Med Univ Vienna, Dept Ophthalmol & Optometry, Vienna, Austria
[2] Jaslok Hosp & Res Ctr, Mumbai, Maharashtra, India
[3] Med Univ Vienna, Ctr Publ Hlth, Vienna, Austria
关键词
Diabetic retinopathy; Diabetic macula edema; Ranibizumab; Triamcinolone; OCT; Fluorescein angiography; OPTICAL COHERENCE TOMOGRAPHY; FLUORESCEIN ANGIOGRAPHY; DEFERRED LASER; VISUAL-ACUITY; PATTERNS; OUTCOMES; PROMPT;
D O I
10.1007/s00417-017-3828-1
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose Our purpose was to compare the impact in diabetic macula edema (DME) of two intravitreal drugs (0.5 mg ranibizumab vs. 8 mg triamcinolone) on changes in retinal morphology in spectral-domain optical coherence tomography (SD OCT) images, color fundus photography (CF) and fluorescein angiography (FA) images during a 1-year follow-up. Methods Post hoc analysis was conducted of morphologic characteristics in OCT, FA and CF images of eyes with a center involving DME that were included in a prospective double-masked randomized trial. Eligible patients were divided at random into two groups receiving either pro re nata treatment with 0.5 mg ranibizumab or 8 mg triamcinolone after a fixed loading dose. OCT and CF images were acquired at monthly visits and FA images every three months. Results Twenty-five eyes of 25 patients (ranibizumab: n = 10; triamcinolone: n = 15) were included in this study. Patients treated with ranibizumab showed better visual acuity results after 12 months than patients receiving triamcinolone (p = 0.015) although edema reduction was similar (p = 0.426) in both groups. The initial effect on macular edema shedding after a single ranibizumab injection could be amplified with the following two injections of the loading dose. After a single injection of triamcinolone the beneficial initial effect on the macula edema faded within 3 months. Subretinal fluid and INL cystoid spaces diminished early in the course of treatment while fluid accumulation in the ONL seemed to be more persistent in both treatment arms. In FA, the area of leakage diminished significantly in both treatment arms. After repeated injections the morphologic OCT and FA characteristics of the treatment arms converged. Conclusions Despite the higher dosage of triamcinolone, both therapies were safe and effective for treating diabetic macular edema. Fluid accumulation in the INL and subretinal space was more responsive to therapy than fluid accumulation in the ONL.
引用
收藏
页码:49 / 58
页数:10
相关论文
共 50 条
  • [41] Impact of Cataract Surgery during Treatment with Ranibizumab in Patients with Diabetic Macular Edema
    Moshfeghi, Andrew A.
    Shapiro, Howard
    Lemmon, Linda A.
    Gune, Shamika
    OPHTHALMOLOGY RETINA, 2018, 2 (02): : 86 - 90
  • [42] Effects of dexamethasone treatment on serous retinal detachment in ranibizumab-resistant diabetic macular edema
    Bayat, Alper Halil
    Elcioglu, Mustafa Nuri
    THERAPEUTIC ADVANCES IN OPHTHALMOLOGY, 2020, 12
  • [43] RETINAL LAYER RESPONSE TO RANIBIZUMAB DURING TREATMENT OF DIABETIC MACULAR EDEMA Thinner is Not Always Better
    Ebneter, Andreas
    Wolf, Sebastian
    Abhishek, Jain
    Zinkernagel, Martin S.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2016, 36 (07): : 1314 - 1323
  • [44] Factors influencing intravitreal bevacizumab and triamcinolone treatment in patients with diabetic macular edema
    Kim, Tai K.
    Shin, Hye Y.
    Kim, Su Y.
    Lee, Young C.
    Lee, Mee Y.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2017, 27 (06) : 746 - 750
  • [46] Intravitreal ranibizumab reduced ocular blood flow and aqueous cytokine levels and improved retinal morphology in patients with diabetic macular edema
    Mizui, Toru
    Noma, Hidetaka
    Yasuda, Kanako
    Kanemaki, Tomoe
    Goto, Hiroshi
    Shimura, Masahiko
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [47] Intravitreal ranibizumab reduced ocular blood flow and aqueous cytokine levels and improved retinal morphology in patients with diabetic macular edema
    Toru Mizui
    Hidetaka Noma
    Kanako Yasuda
    Tomoe Kanemaki
    Hiroshi Goto
    Masahiko Shimura
    Scientific Reports, 10
  • [48] SYSTEMIC SAFETY OF RANIBIZUMAB FOR DIABETIC MACULAR EDEMA Meta-analysis of Randomized Trials
    Yanagida, Yasuko
    Ueta, Takashi
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2014, 34 (04): : 629 - 635
  • [49] Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema
    Elman, Michael J.
    Aiello, Lloyd Paul
    Beck, Roy W.
    Bressler, Neil M.
    Bressler, Susan B.
    Edwards, Allison R.
    Ferris, Frederick L., III
    Friedman, Scott M.
    Glassman, Adam R.
    Miller, Kellee M.
    Scott, Ingrid U.
    Stockdale, Cynthia R.
    Sun, Jennifer K.
    OPHTHALMOLOGY, 2010, 117 (06) : 1064 - U65
  • [50] Comparison of Intravitreal Triamcinolone Treatment and Intravitreal Triamcinolone with Grid Laser Treatment in Patients with Diffuse Diabetic Macular Edema
    Tufan, Hasan Ali
    Ozdek, Sengul
    Hasanreisoglu, Berati
    BALKAN MEDICAL JOURNAL, 2012, 29 (02) : 166 - 169